Downloads: 18

Files in This Item:
File Description SizeFormat 
cancers11121891.pdf3.1 MBAdobe PDFView/Open
Title: Microrna-9-5p-CDX2 axis: A useful prognostic biomarker for patients with stage II/III colorectal cancer
Authors: Nishiuchi, Aya
Hisamori, Shigeo
Sakaguchi, Masazumi
Fukuyama, Keita
Hoshino, Nobuaki
Itatani, Yoshiro  kyouindb  KAKEN_id  orcid (unconfirmed)
Honma, Shusaku
Maekawa, Hisatsugu
Nishigori, Tatsuto
Tsunoda, Shigeru  kyouindb  KAKEN_id
Obama, Kazutaka
Miyoshi, Hiroyuki
Shimono, Yohei
Mark Taketo, M.
Sakai, Yoshiharu
Author's alias: 久森, 重夫
福山, 啓太
板谷, 喜朗
錦織, 達人
角田, 茂
小濵, 和貴
三好, 弘之
武藤, 誠
坂井, 義治
Keywords: CDX2
stage II/III colorectal cancer
Issue Date: 1-Dec-2019
Publisher: MDPI AG
Journal title: Cancers
Volume: 11
Issue: 12
Thesis number: 1891
Abstract: A lack of caudal-type homeobox transcription factor 2 (CDX2) protein expression has been proposed as a prognostic biomarker for colorectal cancer (CRC). However, the relationship between CDX2 levels and the survival of patients with stage II/III CRC along with the relationship between microRNAs (miRs) and CDX2 expression are unclear. Tissue samples were collected from patients with stage II/III CRC surgically treated at Kyoto University Hospital. CDX2 expression was semi-quantitatively evaluated by immunohistochemistry (IHC). The prognostic impacts of CDX2 expression on overall survival (OS) and relapse-free survival (RFS) were evaluated by multivariable statistical analysis. The expression of miRs regulating CDX2 expression and their prognostic impacts were analyzed using The Cancer Genome Atlas Program for CRC (TCGA-CRC). Eleven of 174 CRC tissues lacked CDX2 expression. The five-year OS and RFS rates of patients with CDX2-negative CRC were significantly lower than those of CDX2-positive patients. Multivariate analysis of clinicopathological features revealed that CDX2-negative status is an independent marker of poor prognosis in stage II/III CRC. miR-9-5p was shown to regulate CDX2 expression. TCGA-CRC analysis showed that high miR-9-5p expression was significantly associated with poor patient prognosis in stage II/III CRC. In conclusion, CDX2, the post-transcriptional target of microRNA-9-5p, is a useful prognostic biomarker in patients with stage II/III CRC.
Rights: © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
DOI(Published Version): 10.3390/cancers11121891
PubMed ID: 31783700
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.